Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Por um escritor misterioso
Descrição
Reprogramming the pancreatic cancer stroma and immune landscape by a silicasome nanocarrier delivering nintedanib, a protein tyrosine kinase inhibitor - ScienceDirect
T cells dominate the intratumoral immune cell infiltrate. A)
The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy - The Lancet Gastroenterology & Hepatology
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies - Anthony Turpin, Cindy Neuzillet, Elise Colle, Nelson Dusetti, Rémy Nicolle, Jérôme Cros, Louis de Mestier, Jean-Baptiste Bachet, Pascal Hammel, 2022
Current and Evolving Therapies for Metastatic Pancreatic Cancer: Are We Stuck With Cytotoxic Chemotherapy?
Myeloid immunosuppression and immune checkpoints in the tumor microenvironment
Frontiers Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy
The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers - Ren - 2023 - MedComm - Wiley Online Library
de
por adulto (o preço varia de acordo com o tamanho do grupo)
